Article
Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.
Clinical chemistry - 3 Sept 2025
Chun Jung Won, Lee Dong-Eun, Kim Min Kyeong, Hwang Jin-Hyeok, Lee Sang Hyub, Jung Min Kyu, Kim Eui Joo, Ahn Dong-Won, Kim Yun-Hee, Han Sung-Sik, Park Sang-Jae, Lee Woo Jin, Woo Sang Myung, Kong Sun-Young
Abstract excerpt
BACKGROUND: The generalizability and applicability of circulating tumor DNA (ctDNA) KRAS mutations in patients with pancreatic adenocarcinoma (PAC) remain elusive. We aimed to propose a cut-off value of mutant KRAS (mKRAS) concentration in ctDNA and validate its clinical utility. METHODS: This prospective, multicenter cohort study enrolled 419 patients with PAC. mKRAS was determined using multiplex droplet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.